To evaluate the in vivo efficacy of ASO-Snrnp200, we generated 4T1 xenograft tumors by injecting 5 × 105 4T mouse breast cancer cell lines into mice treated with ASO-Snrnp200, which exhibited a substantial reduction in tumor growth compared with that in PBS-treated controls (Fig. 2i, j). Here, SNRNP200 is linked to breast carcinoma.